PDL BioPharma Earnings: Here’s Why Shares are Up Now

PDL BioPharma, Inc. (NASDAQ:PDLI) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 2%.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

PDL BioPharma, Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased 24.14% to $0.36 in the quarter versus EPS of $0.29 in the year-earlier quarter.

Revenue: Rose 18.7% to $91.8 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: PDL BioPharma, Inc. reported adjusted EPS income of $0.36 per share. By that measure, the company beat the mean analyst estimate of $0.35. It beat the average revenue estimate of $91.69 million.

Quoting Management: There was no comment from management.

Key Stats (on next page)…

Revenue increased 6.68% from $86.05 million in the previous quarter. EPS increased 5.88% from $0.34 in the previous quarter.

Looking Forward: Analysts have a neutral outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings is a profit of $0.53 and has not changed. For the current year, the average estimate has moved up from a profit of $1.58 to a profit of $1.61 over the last ninety days.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)